SavedAdd your journal

Journals / Viral Hepatitis Journal / 2014 / Cilt: 20 - Sayı: 3

Kronik Hepatit B Hastasında Peginterferon Alfa-2a Tedavisi Esnasında Gelişen Kaşık Tırnak

Koilonychia Developed in a Patient with Chronic Hepatitis B During Peginterferon Alfa-2a Treatment

AZİZ ÖĞÜTLÜ
HASAN TAHSİN GÖZDAŞ
Oğuz KARABAY
Pages
138–139
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Here, we report the case of a patient with chronic hepatitis B who developed spooning (koilonychia) during PEG-IFN α-2a treatment in the absence of anemia.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:There are many adverse effects associated with peginterferon alfa-2a (PEG-IFN α-2a) treatment.
📊
Key Findings & Data:The most common side effects are flu-like disease, gastrointestinal distress, weight loss, and anemia.
💡
Conclusion & Impact:Here, we report the case of a patient with chronic hepatitis B who developed spooning (koilonychia) during PEG-IFN α-2a treatment in the absence of anemia.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

There are many adverse effects associated with peginterferon alfa-2a (PEG-IFN α-2a) treatment. The most common side effects are flu-like disease, gastrointestinal distress, weight loss, and anemia. Here, we report the case of a patient with chronic hepatitis B who developed spooning (koilonychia) during PEG-IFN α-2a treatment in the absence of anemia.

Özet

Peginterferon alfa-2a (PEG-IFN α-2a) tedavisine bağlı birçok yan etki mevcuttur. En sık görülen yan etkiler grip benzeri hastalık, gastrointestinal bozukluk, kilo kaybı ve anemidir. Biz burada, PEG-IFN α-2a tedavisi esnasında anemi olmaksızın kaşık tırnak geliştiren kronik hepatit B olgusunu bildiriyoruz.

🔖

Cite This Article

ÖĞÜTLÜ, A., GÖZDAŞ, H. T., KARABAY, O. (2014). Kronik Hepatit B Hastasında Peginterferon Alfa-2a Tedavisi Esnasında Gelişen Kaşık Tırnak. Viral Hepatitis Journal, Cilt: 20 - Sayı: 3, 138–139. https://ajindex.com/articles/332734

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. kartal eD, alpat Sn, ozgunes I, usluer G. adverse effects of high-dose interferon-alpha-2a treatment for chronic hepatitis B. adv Ther. 2007; 24:963-971
  2. Schaefer M, Mauss S. hepatitis C treatment in patients with drug addiction:clinical management of interferon-alpha- associated psychiatric side effects. Curr Drug abuse Rev. 2008; 1: 177-187
  3. Mistry n, Shapero J, Crawford RI. a review of adverse cutaneous drug reactions resulting from the use of interferon and ribavirin. Can J Gastroenterol. 2009; 23: 677-683
  4. Tavakoli-Tabasi S, Bagree a. a longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C. J Clin Gastroenterol. 2012; 46: 162- 167
  5. Federico a, Sgambato D, Cotticelli G, Gravina aG, Dallio M, Beneduce F, Ruocco e, Romano M, loguercio C. Skin adverse events During Dual and Triple Therapy for hCv-Related Cirrhosis. hepat Mon. 2014;14:16632
  6. Ginder GD. Microcytic and hypochromic anemias. In Goldman l, ausiello Da. Cecil Medicine, 23rd. edition, Philadelphia: Saunders elsevier, 2007;1187-1194
  7. Misery l. Diffuse hypertrichosis in the course of hepatitis C treatment by IFn-alpha and ribavirin. J Interferon Cytokine Res. 2002; 22: 881-882
  8. Cacoub P, Bourliere M, lübbe J, Dupin n, Buggisch P, Dusheiko G, hézode C, Picard o, Pujol R, Segaert S, Thio B, Roujeau JC. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J hepatol. 2012; 56: 455-463.